|
|
||||||||
Developmental Neurobiology Unit, Division of Child and Adolescent Psychiatry, Department of Psychiatry, Bellevue Hospital Center and New York University Medical Center, New York, NY.
In an open, nonblind clinical trial, clomipramine reduced adventitious movements and compulsions in five previously medicated prepubertal boys with autistic disorder and severe mental retardation. Poorly adapted rating scales, interrater variability, subject heterogeneity, different treatment histories, and environmental stresses confounded the assessment of treatment effects.
Address correspondence and reprint requests to Dr. James R. Brasic, Department of Psychiatry, New York University School of Medicine, 550 First Avenue, New York, NY 10016.
Presented in part at the 45th annual meeting of the American Academy of Neurology, New York, NY, April 1993.
Supported by a grant from the Medical Fellows Program of the Consortium for Medical Education in Developmental Disabilities of the Office of Mental Retardation and Developmental Disabilities of the State of New York.
Received July 9, 1993. Accepted in final form January 5, 1994.
This article has been cited by other articles:
![]() |
R Antochi, C Stavrakaki, and P C Emery Psychopharmacological treatments in persons with dual diagnosis of psychiatric disorders and developmental disabilities Postgrad. Med. J., March 1, 2003; 79(929): 139 - 146. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Brasic and J. G. Gianutsos Neuromotor Assessment and Autistic Disorder Autism, September 1, 2000; 4(3): 287 - 298. [Abstract] [PDF] |
||||
![]() |
L. Y. Tsai Psychopharmacology in Autism Psychosom Med, September 1, 1999; 61(5): 651 - 665. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |